202 research outputs found

    Innovation in smallholder farming in Africa: recent advances and recommendations: Proceedings of the International Workshop on Agricultural Innovation Systems in Africa (AISA)

    Get PDF
    In the wake of a series of recent international events and initiatives focusing on understanding and fostering innovation1, there is growing awareness and interest in applying and making sense of the Agricultural Innovation Systems (AIS) concepts and perspectives and what they offer for understanding and supporting innovation systems, processes and networks. This has particular relevance for African agriculture as it faces several challenges, such as increasing and intensifying food production in a sustainable way and nourishing its fast-growing population, adapting to the consequences of climate change, and finding its rightful place in an increasingly global and complex international scene. Several initiatives and programmes seeking answers to these questions jointly organised a series of events during a Week on Agricultural Innovation in Africa (WAIA) held in Nairobi, Kenya, on 25–31 May 2013, of which the international workshop on Agricultural Innovation Systems in Africa (AISA) on 29–31 May was a major part. Another key event during this week, was the Eastern African Farmer Innovation Fair (EAFIF) held on 28–29 May, which was linked to AISA

    A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels

    Get PDF
    PURPOSE OF THE STUDY: Statins and ezetimibe reduce low-density lipoprotein cholesterol (LDL-c) and cardiovascular disease (CVD) risk. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors lower LDL-c by 50%-70% and might be useful in refractory patients. The National Institute for Health and Care Excellence (NICE) technology appraisal guidance (TAG) recommends use of these drugs in secondary prevention and familial hypercholesterolaemia (FH) at differing LDL-c thresholds. We have estimated the proportion of patients in whom this third-line drug might be useful. STUDY DESIGN: We used data from a lipid-lowering audit programme to study 72 with FH and/or CVD of 271 patients referred over 12 months who failed to achieve target total cholesterol (TC) and LDL-c levels. All 72 patients were treated with ezetimibe, and 69 cases also received statins. We used LDL-c thresholds 1.5-5.5 mmol/L to estimate how many of these refractory patients could benefit from PCSK9 inhibitors. RESULTS: In 72 patients, TC and LDL-c targets were not met by 64 and 53 patients, respectively. We judged using the NICE TAG that only one patient (1.4% ezetimibe requiring and 0.4% total referrals) required a PCSK9 inhibitor. CONCLUSIONS: We determined that the proportion of patients eligible for a PCSK9 inhibitor at various TC and LDL-c levels is modest. This may reflect the use of all available statins in UK lipid clinics often at non-daily frequency. We suggest that cost-effective use of PCSK9 inhibitors requires prescribing being restricted to clinicians working in specialised lipid clinics

    tRNAs Promote Nuclear Import of HIV-1 Intracellular Reverse Transcription Complexes

    Get PDF
    Infection of non-dividing cells is a biological property of HIV-1 crucial for virus transmission and AIDS pathogenesis. This property depends on nuclear import of the intracellular reverse transcription and pre-integration complexes (RTCs/PICs). To identify cellular factors involved in nuclear import of HIV-1 RTCs, cytosolic extracts were fractionated by chromatography and import activity examined by the nuclear import assay. A near-homogeneous fraction was obtained, which was active in inducing nuclear import of purified and labeled RTCs. The active fraction contained tRNAs, mostly with defective 3′ CCA ends. Such tRNAs promoted HIV-1 RTC nuclear import when synthesized in vitro. Active tRNAs were incorporated into and recovered from virus particles. Mutational analyses indicated that the anticodon loop mediated binding to the viral complex whereas the T-arm may interact with cellular factors involved in nuclear import. These tRNA species efficiently accumulated into the nucleus on their own in a energy- and temperature-dependent way. An HIV-1 mutant containing MLV gag did not incorporate tRNA species capable of inducing HIV-1 RTC nuclear import and failed to infect cell cycle–arrested cells. Here we provide evidence that at least some tRNA species can be imported into the nucleus of human cells and promote HIV-1 nuclear import

    The properties of the first galaxies in the BlueTides simulation

    Get PDF
    We employ the very large cosmological hydrodynamical simulation BlueTides to investigate the predicted properties of the galaxy population during the epoch of reionization (z > 8). BlueTides has a resolution and volume ((400/h ≈ 577)3 cMpc3) providing a population of galaxies that is well matched to depth and area of current observational surveys targeting the high-redshift Universe. At z = 8, BlueTides includes almost 160 000 galaxies with stellar masses >108 M⊙. The population of galaxies predicted by BlueTides closely matches observational constraints on both the galaxy stellar mass function and far-UV (150 nm) luminosity function. Galaxies in BlueTides are characterized by rapidly increasing star formation histories. Specific star formation rates decrease with redshift though remain largely insensitive to stellar mass. As a result of the enhanced surface density of metals, more massive galaxies are predicted to have higher dust attenuation resulting in a significant steepening of the observed far-UV luminosity function at high luminosities. The contribution of active supermassive black holes (SMBHs) to the UV luminosities of galaxies with stellar masses 109–10 M⊙ is around 3 per cent on average. Approximately 25 per cent of galaxies with M∗ ≈ 1010 M⊙ are predicted to have active SMBHs that contribute >10 per cent of the total UV luminosity
    corecore